Regulatory Considerations of Biosimilars and Clinical Dilema of Their Use

SANAMED
doi 10.24125/sanamed.v1i1.158
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Association of Medical Doctors Sanamed

Related search

Biosimilars: Key Regulatory Considerations and Similarity Assessment Tools

Biotechnology and Bioengineering
Applied MicrobiologyBiotechnologyBioengineering
2017English

Demystifying Biosimilars: Development, Regulation and Clinical Use

Future Oncology
MedicineCancer ResearchOncology
2019English

Clinical Use of Irinotecan:Current Status and Future Considerations

Oncologist
Cancer ResearchMedicineOncology
1997English

Special Population Considerations and Regulatory Affairs for Clinical Research

Clinical Research and Regulatory Affairs
PharmacologyPharmaceutical Science
2015English

Will Regulatory and Financial Considerations Dampen Innovation in the Clinical Microbiology Laboratory?

mBio
VirologyMicrobiology
2016English

Regulatory Requirements for the Development and Registration of Biosimilars in South Africa

GaBI Journal
Drug GuidesPharmacy
2015English

Considerations for the Use of Mutation as a Regulatory Endpoint in Risk Assessment

Environmental and Molecular Mutagenesis
MutagenesisToxicologyHealthGeneticsEpidemiology
2019English

An Examination of the Regulatory and Reimbursement Processes for Biobetters and Comparison With Biosimilars

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Cannabis Vaping and Health: Regulatory Considerations

Addiction
MedicinePsychiatryMental Health
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy